Topical transdermal administration of lenalidomide nanosuspensions-based hydrogels against melanoma: In vitro and in vivo studies.

Int J Pharm X · 2025 · PMC11787432 · PMID 39898009

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

After 30 days of treatment, serum was collected for testing, revealing a decreasing trend in TNF-α (Fig.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.